期刊
INFECTIOUS DISEASES IN CLINICAL PRACTICE
卷 29, 期 5, 页码 E305-E306出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/IPC.0000000000000991
关键词
SARS-CoV-2; Strongyloides hyperinfection syndrome; corticosteroid treatment
Eosinopenia is frequently seen in patients with COVID-19, even in those with chronic eosinophilia. Screening for strongyloidiasis is recommended for all patients eligible for immunosuppressive therapy to prevent Strongyloides hyperinfection syndrome.
Eosinopenia was frequently encountered in patients with coronavirus disease 2019 (COVID-19). We describe a case of a 59-year-old man who was treated with high-dose corticosteroids and anti-interleukin 1 receptor antagonist therapy because of severe acute respiratory distress syndrome due to a so-called cytokine storm in COVID-19. He had chronic eosinophilia for many years due to an unknown Strongyloides stercoralis infection, proven by serology and a positive polymerase chain reaction test on a stool sample. COVID-19 led to a complete resolution of eosinophilia, even before immunosuppressive treatment was started. Eosinophilia returned after recovery from COVID-19 and started to decline under treatment with ivermectin. Our case confirms previous reports of eosinopenia in COVID-19, as it appears even in patients with chronic eosinophilia. Presence of eosinophilia should prompt screening for strongyloidiasis in all patients eligible for immunosuppressive therapy because of the risk of Strongyloides hyperinfection syndrome, especially if this treatment is empirical.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据